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physical functioning (PF), general health (GH), vitality (VT) and mental health (MH) 
subscales. Multiple linear regressions were used to assess the association between usage 
patterns, HRQoL scores and other sociodemographic, health behavior and health service 
utilization characteristics. RESULTS: Of 7158 women retained at Survey 4, 885 were 
identiﬁ ed as having diabetes with overall prevalence of cardiovascular medication use 
of 89.9%. After adjusting for other covariates, being on three classes of cardiovascular 
medications was signiﬁ cantly associated with increased scores on PF (coefﬁ cient 16.134, 
95% CI 6.940–25.327), GH (10.058, 95% CI 2.649–17.468) and MH (12.896, 95% 
CI 6.562–15.882) subscales. Being on any two classes was associated with increased 
scores on PF and GH (coefﬁ cient 14.744, 95% CI 5.988–23.501 and 8.334, 95% CI 
1.200–15.467, respectively), whereas using single cardiovascular drug was only signiﬁ -
cantly associated with increased scores on PF (coefﬁ cient 12.346, 95% CI 3.943–
20.750). CONCLUSIONS: Intensive use of cardiovasular medications to support 
diabetes management was shown to be subjectively beneﬁ cial. Concern about perceived 
deterioration on HRQoL attributable to pill burden might be captured if a diabetes-
speciﬁ c instrument was employed. 
PDB21
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OBJECTIVES: CBIA is a small group discussion which emphasizes on the active role 
of participants in looking for information. CBIA has been proven effective to improve 
tuberculosis patient’s adherence to treatment program, pharmacy assistant’s skills in 
hypertension drug information service, and skills in early detection of Brest cancer. 
Therefore, CBIA was developed adapting the original CBIA, enriched with key mes-
sages in healthy life-style for diabetic patients as CBIA-DM. This study was aimed to 
assess the impact of CBIA-DM on diabetic patients’ quality of life. METHODS: Time 
series, pre and post quasi-experimental design. Three groups were involved in the 
study: CBIA-DM, DM-club and normal-care group. Data were collected in pre-
intervention, immediately, one, three and 6 months post intervention using WHO-
QOL-bref questionnaires Bahasa version. Categorizing scores in good (>mean + SD), 
fair (between mean + SD and mean − SD), and poor (<mean − SD) level. Effectiveness 
of CBIA-DM was assessed based on the increasing of participant number in good level 
which steady remains until 6 months post-intervention, time-required and cost/person 
for conducting CBIA-DM, and acceptance of CBIA-DM by the participants. RESULTS: 
In general quality of life, participant number of CBIA-DM (n = 30) increased from 
13.3% to 16.7%. In health status: general, physical, psychological, social-relation-
ships, and environment, increased from 23.3% to 40%, 13.3% to 23.3%, 16.7% to 
23.3%, 16.7% to 30%, and 16.7% to 26.7% respectively. Time-required for conduct-
ing CBIA-DM was one-third (3 vs. 9 hours) with cost/person 0.28 (US D 6.50 vs 
22.75) compared to DM-club. Participants expressed that CBIA-DM was enjoyable. 
CONCLUSIONS: CBIA-DM is cost effective strategy and has positive-impact on 
diabetic patients’ quality of life. 
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OBJECTIVES: To assess utilization and prescribing patterns of antidiabetics in 
Taiwan. METHODS: This cross-sectional study used the Taiwanese Diabetic Pay-for-
performance Register to extract a diabetic outpatient claim dataset from the National 
Health Insurance reimbursement data. Adult diabetic patients with at least one antidia-
betic prescription during 2004 to 2008 were indentiﬁ ed and prescription details were 
collected. Antidiabetic drugs were stratiﬁ ed by into injection (insulin) and ﬁ ve chemical 
groups of oral drugs. Pattern of antidiabetic combination was categorized by both type 
and number of combined drugs. Frequency of different prescribing pattern was calcu-
lated and presented as annual prescribing rate and analyzed by Cochran-Armitage trend 
test to test a signiﬁ cant ascending or descending trends. All data was processed in SAS 
9.1. 3. RESULTS: Over 95% prescribing patterns was composed of monotherapy, 
combination of any two, and combination of any three antidiabetics with approximate 
30%, 47%, and 18% annual prescription rate, respectively. The most frequent types 
of drugs within above three patterns included single sulfonylurea (SU1), combined one 
biguanide and one sulfonylurea (BG1+SU1), and combined one biguanide, one sulfo-
nylurea and one thiazolidinedione (BG1 + SU1 + TZD1). Prescribing rates of SU1 
(from 18.1% to 9.83%) and BG1 + SU1 (from 37.6% to 34.46%) decreased over the 
study period (P < 0.001), but BG1 + SU1 + TZD1 revealed an increasing trend (from 
8.45% to 10.99%, P < 0.001). Any prescribing pattern containing insulin presented 
an incremental annual prescribing rate, but the prescribing rates for those only con-
sisted of oral antidiabetics declined over time. CONCLUSIONS: Antidiabetic prescrib-
ing patterns in Taiwan have changed and shifted from simple monotherapy to multiple 
combinations of newer drugs. Meanwhile, prescribing rates of single-use or combine-
use insulin have also risen. It is necessary to further investigate the impacts of change 
prescription patterns on diabetic complications. 
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OBJECTIVES: Diabetes has become one of the major chronic diseases of the 21st 
century, and has ranked ﬁ fth on the main causes of death in Taiwan for years. The 
high cost of antidiabetic medications expenditure has brought the concern on 
the generic and brand drugs substitution. The purpose of the study was to investigate 
the effects of hospital drug brands changes on physicians’ prescription behavior and 
patients’ outcomes. METHODS: The study was conducted at a medical center in 
Taipei city. We recruited those who had taken the same medicine regularly from 
January 2004 to June 2004. In the next 4 years, the study hospital had changed the 
manufactures of metformin four times. Physicians’ prescription data and patients’ 
glycated hemoglobin values were collected. We retrospectively analyzed the prescrip-
tion patterns for oral antidiabetes medications of patients with persistence medication 
service in ﬁ ve different metformin brand stages. RESULTS: The results show 1) the 
average item of anti-diabetes drugs in each prescription was signiﬁ cantly increased; 2) 
the prescription rates were signiﬁ cant increased for acarbose and insulin, and decreased 
for metformin, glibenclamide and rosiglitazone; 3) The daily dose of metformin, which 
was on average between 1565 mg and 1611 mg, wasn’t increased signiﬁ cantly regard-
less of the change in manufacturers; and 4) The HbA1c values of study patients were 
increasing, but no signiﬁ cant difference was observed in different metformin brand 
stages. CONCLUSIONS: The use of generic drugs can effectively reduce the cost of 
medication. The results provide information for hospital administrators in drug pur-
chasing and price negotiating with the manufacturers. 
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OBJECTIVES: To study the transition time of patients with Type 2 diabetes mellitus 
(T2DM) progressing from “good” to “poor” glycemic control and its association with 
the number and type of diabetes-related vascular diseases such as coronary heart 
disease, stroke, eye complications, peripheral vascular disease, and nephropathy. 
METHODS: In this retrospective study, data from a disease registry were used. A 
cohort of T2DM patients who had attended either a hospital specialist clinic or a 
primary care diabetes service, and deemed to have “good” control (at least two 
consecutive HbA1c ≤ 7%) from October 2005 to March 2006 were included in this 
study. Patients were subsequently followed up for a period of 4 years. Time to “poor” 
glycemic control (HbA1c > 8%) for each diabetes-related vascular disease was calcu-
lated using Kaplan–Meier analysis. Hazards Ratio (HR) was adjusted for age, gender, 
ethnicity, BMI, duration of diabetes, baseline HbA1c, LDL-cholesterol and insulin use 
using Multivariate Cox analysis. RESULTS: There were 7739 T2DM patients, with 
median age of 68 years and baseline HbA1c of 6.4%. Over a quarter (28.9%) of 
patients reached “poor” control at the end of 4 years, with a median time of 575 days 
(95% CI: 550–600). Multivariate Cox regression analysis suggested that likelihood of 
“poor” control was increased with each additional diabetes-related vascular disease 
(AdjHR 1.14, 95% CI: 1.07–1.23) and higher for eye complications (AdjHR 1.47, 
95%CI: 1.17–1.86) and nephropathy (AdjHR 1.43, 95% CI:1.06–1.93). CONCLU-
SIONS: Despite starting with “good” glycemic control, 3 out of 10 T2DM patients 
progressed to “poor” glycemic control at the end of 4 years of study. Patients with 
more diabetes-related vascular diseases were at higher risk of progressing to “poor” 
control, particularly those with microvascular complications. 
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OBJECTIVES: Type 2 diabetes mellitus (T2DM) patients often have co-existing hyper-
tension and dyslipidemia and some develop retinopathy, peripheral vascular disease 
(PVD), stroke, nephropathy and coronary heart disease (CAD). This study investigates 
the prevalence of these conditions which are associated with T2DM and the associa-
tion with optimal glycemic control (HbA1c up to 7%). METHODS: This is a cross-
sectional study. We included all T2DM patients who were treated at the specialist 
outpatient clinics (SOCs) in three public-sector hospitals in Singapore during January 
2009 and were on follow-up at the same clinic for at least 12 months. All data were 
extracted from the National Healthcare Group (NHG) Diabetes Registry (CDMS), 
including the medical diagnosis and HbA1c result at the last visit. We compared the 
distribution of glycemic control for each diabetes-related condition and performed 
logistic regression for “optimal” glycemic control adjusting for age, gender and ethnic-
ity. RESULTS: Of the 3420 T2DM patients, 2919 (85%) with HbA1c results were 
analyzed. Mean age was 63.2 years, with 53% female and 66% Chinese, high preva-
lence of dyslipidemia (92.7%) and hypertension (74.5%). About 1249 (42.8%) 
patients had “optimal” glycemic control. CAD (28.7%) was the most common condi-
tion, followed by PVD (22.5%), retinopathy (21.8%), nephropathy (14.4%) and 
stroke (10.7%). The Malay group had the highest proportion of hypertension 
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(78.8%), retinopathy (27.9%) and nephropathy (22.2%); Indian were highest in PVD 
(26.8%), and CAD (34.4%); Chinese highest in stroke (12.1%). After adjusting for 
age, gender and ethnicity, the odds of having “optimal” glycemic control was higher 
for T2DM patients with nephropathy (Adj OR:1.50; 95% CI [1.19–1.89]) and stroke 
(Adj OR:1.51; 95% CI [1.17–1.96]) compared to PVD (Adj OR: 0.61; 95% CI 
[0.51–0.74]) and retinopathy (Adj OR: 0.65; 95% CI [0.53–0.79]). CONCLUSIONS: 
There were ethnic differences in the prevalence of diabetes-related complications. 
T2DM patients with stroke or nephropathy were more likely to achieve “optimal” 
HbA1c level than those with PVD or eye complications. 
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OBJECTIVES: Health technology Assessment (HTA) has a long history in Australia and 
NZ and is rapidly evolving in Asian countries. The aim of this research was to identify 
and review English written reports on diabetes among HTA agencies in Asia and 
Oceania. METHODS: ISPORs directory (http://www.ispor.org) listing worldwide HTA 
organizations were searched for agencies in Asia and Oceania with a valid link to a 
webpage were included. On each agencies webpage a search was done using the search 
term “diabetes” and English written assessments were included for further review. 
RESULTS: The following HTA agencies were searched: PBAC, MSAC ASERNIP-S, 
AHTA, CCE, CHERE, HTA, NIPH, CRECON, MAPI, PHIC, PKEBM, ICTACH, 
HSAC, NZHTA, HIRA, CDE and HITAP. Of those, only 14 relevant reports were 
found from Australia, NZ and Thailand. Two were found from PBAC, ﬁ ve from AHTA, 
one from HSAC, two from NZHTA, and four from HITAP. The two reports from PBAC 
were describing how to improve National management of diabetes. The reports from 
AHTA were horizon scanning reports covering glucose monitoring, screening of gesta-
tional diabetes and detecting retinopathy. HSAC had a report on insulin pump whereas 
as NZHTA had one on glucose monitoring and one about clinical features detecting 
insulin resistance. The reports found on HITAP were in the form of published articles 
assessing cost effectiveness of two different antihypertensive therapies in diabetes, one 
assessing cost effectiveness of diabetes management and ﬁ nally one assessing diabetes 
self management. Reports from HSAC, NZHTA and HITAP contained economic 
modeling with QALY as outcome. CONCLUSIONS: Despite of broad search criteria 
only 14 English written reports were found on diabetes. A headline in English on each 
assessment would facilitate information sharing and make it easier to evaluate the need 
for translational support. 
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OBJECTIVES: Due to the effect of National Health Insurance drug price cut policy, 
the studied hospital has changed the manufactures of metformin four times in 5 years 
since July, 2004. The purpose of this study is to investigate the effects of the change 
in hospital drug brands on patients’ utilization and the factors that inﬂ uence patients’ 
persistence on the use of metformin. METHODS: Data were sourced from a medical 
center in Taipei city during 2004–2008. We collected all the oral antidiabetic drugs 
used during the study period and classiﬁ ed them into ﬁ ve categories: Biguanid, Sulfo-
nylures, α-glucosidase inhibitor, Thiazolidinediones, and Meglitinide. The quantity of 
all the antidiabetics used was transformed by using WHO/ATC into DDDs. In this 
study, Metformin was treated as the experimental group and all other antidiabetics 
drugs were the control groups. RESULTS: The results showed that the quantity of 
metformin prescribed was increasing during the study period in spite of the brand 
change. However, other categories of oral antidiabetes were also increasing due to the 
increase in number of patients. The percentage of all types of drug stayed relatively 
steadily, in which metformin itself occupied 21–23%, all Sulfonylureas drugs occupied 
59–60%, α-glucosidase inhibitor occupied 3–4%, Thiazolidinediones occupied 
10–11%, and Meglitinide occupied 4–5% during the study period. In addition, the 
results of logistic regressions showed that female patients with hypertension or hyper-
lipemia between the ages of 40~80 who live in Taipei city performed better persistence 
of seeking medical service. CONCLUSIONS: The results shows changing the brand 
of metformin did not decrease drug consumption and patient numbers. By analyzing 
the acceptance of generic drugs of patients and doctors, this study provides important 
information for hospital administrators and health administrators. 
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OBJECTIVES: To explore current disease status and approach to care for patients 
with type 2 diabetes (T2DM) in China. METHODS: The study was performed using 
data from the Adelphi T2DM Disease Speciﬁ c Programme (DSP©), a cross-sectional 
study of consulting patients providing insights into “real-world” behaviors and atti-
tudes in clinical practice in 2008. The DSP collected data on 1648 patients with T2DM 
receiving at least one oral anti-diabetic with or without insulin and from 200 physi-
cians (140 specialists and 60 internal medicine) across general hospitals in nine 
Chinese cities through physician interviews, patient record forms and patient-
completed questionnaires. RESULTS: Of 1648 patients (50% male, mean [SD] age: 
57.74 [12.56] years, BMI: 24.04 [3.37] kg/m2, duration of diabetes: 4.52 [5.06] years), 
74% had at least one comorbidity, 39% were overweight (24 ≤ BMI < 28 kg/m2) and 
9% were obese (BMI ≥ 28 kg/m2). Sixty-one percent had an HbA1c ≥ 7% and only 
35% of patients were aware of an HbA1c target. 39.20% of patients were treated 
with OAD monotherapy (metformin [Met]: 12.26%, Sulphonyureas [SU]: 12.56%, 
alpha-glucosinase inhibitor [AGI]: 8.37%, prandial glucose regulators [PGR]: 4.67%, 
thiazolidinediones [TZD]: 2.31%) and 29.67% were on dual OAD therapy (com-
monly Met + SU: 11.71%, Met + AGI: 4.37%, SU + AGI: 3.82%, Met + PGR: 4.25%, 
Met + TZD: 1.52%), while 28.09% of patients were on OAD + insulin therapy. Lack 
of gastrointestinal, liver function side effects and hypoglycemia risk, QD dosage, and 
beneﬁ cial effects on blood pressure were the ﬁ ve most cited unmet needs in non-insulin 
diabetes treatment highlighted by physicians. Mean (SD) patient-reported QoL 
(EQ-5D VAS) was 0.86 (0.18) and mean (SD) diabetes treatment satisfaction was 
25.97(5.14)/36 where 0 is very dissatisﬁ ed and 36 very satisﬁ ed. CONCLUSIONS: 
The study population of Chinese T2DM patients is relatively young and recently 
diagnosed. More than half were poorly controlled and the need for further therapeutic 
actions to improve glycemic control as well as better doctor/patient communication 
regarding treatment goals is clear. 
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OBJECTIVES: Examine BMI and achievement of diabetes treatment targets in patients 
with Type 2 Diabetes (T2DM). METHODS: The study used the 2008 Adelphi T2DM 
Disease Speciﬁ c Programme© a cross-sectional study of consulting patients providing 
insights into ‘real-world’ behaviors and attitudes in clinical practice. Data was col-
lected on 1648 patients with T2DM receiving at least one oral anti-diabetic with/
without insulin and 140 specialists and 60 internal medicine physicians distributed 
across general hospitals in nine Chinese cities through physician interviews, patient 
record forms and self-completed questionnaires. RESULTS: Across the 1648 patients 
in the study; mean (SD) age was 57.7 (12.6) years, 46% were ≤2 years from diagnosis 
and mean (SD) BMI was 24.0 (3.4) kg/m2. Nine percent of patients were obese (BMI 
≥ 28 kg/m2), 39% overweight (24 ≤ BMI < 28 kg/m2) and 51% normal/underweight 
(BMI < 24 kg/m2). Prevalence of comorbidities in this population was high; 49% 
reporting hypertension and 42% dyslipidemia (25% patients reported both). Glycemic 
control appeared worse in patients with a higher BMI. Twenty-two percent of patients 
with a BMI ≥ 28 had an HbA1c ≥ 9% and 39% had an HbA1c ≥ 8% compared to 
10% of patients with a BMI between 19–27.9 having an HbA1c ≥ 9% and 22% 
having an HbA1c ≥ 8%. Only 35% of patients were aware of having an HbA1c target 
set by their physician. Comorbid conditions were more prevalent in overweight and 
obese patients. Among normal weight patients 31% reported no comorbid conditions 
compared to 22% of overweight patients and 17% of obese patients. Prevalence of 
hypertension, dyslipidemia and other macrovascular conditions were 44%, 36%, and 
18% respectively among normal weight patients; 53%, 48%, and 19% among over-
weight patients and 65%, 55%, and 24% among obese patients. CONCLUSIONS: 
The results indicate that obese patients report higher HbA1c and higher rates of 
complications compared to the normal weight patients and strategies to improve target 
better outcomes could include managing obesity. 
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OBJECTIVES: An objective of this review was to assess clinical efﬁ cacy in terms of 
“HBeAg seroconversion” of treatment options for HBeAg-positive chronic hepatitis 
B (CHB). METHODS: A systematic review of randomized controlled trials (RCTs) of 
treatments for patients with HBeAg-positive CHB was performed through the Medline 
and Cochrane databases. The clinical studies were included only if they assessed the 
efﬁ cacy among the following treatment options namely 1) lamivudine; 2) entecavir; 
3) interferon; and 4) interferon plus lamivudine. Indirect or mixed-treatment compari-
son meta-analysis with random effect model was employed to combine results of 
several studies. The meta-analysis was carried out using the WinBUGS14 software. 
Odds ratio (OR) and its 95% conﬁ dence interval (CI) were presented. Heterogeneity 
test was applied for testing the variation of study outcomes between studies. RESULTS: 
There were 115 abstracts reviewed with eight relevant RCTs included in the analysis. 
None of eight RCTs included all four treatment options. Five studies compared HBeAg 
seroconversion between entecavir and lamivudine. There were three different studies 
comparing interferon with interferon plus lamivudine, interferon plus lamivudine with 
lamivudine, and interferon and interferon plus lamivudine with lamivudine. Indirect 
